Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

449
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
449
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

247
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
247
Dosage Interval and Administration Route: Determination Methods01:19

Dosage Interval and Administration Route: Determination Methods

406
A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to...
406
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

487
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
487
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.8K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.8K
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

314
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
314

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From laboratory to field: integrating real-world particle size into exposure-relevant agrochemical occupational risk assessment.

Inhalation toxicology·2026
Same author

Derivation of an occupational exposure limit (OEL) for a potent bispecific protein-Blinatumomab (BLINCYTO®).

Regulatory toxicology and pharmacology : RTP·2026
Same author

Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity data.

Regulatory toxicology and pharmacology : RTP·2026
Same author

Trends in the distribution of P values in epidemiology journals: a statistical, P-curve, and simulation study.

American journal of epidemiology·2025
Same author

Evaluating the lifetime cumulative dose as a basis for carcinogenic potency of nitrosamines - a key tenet underpinning less-than-lifetime approaches for establishing acceptable intake limits.

Regulatory toxicology and pharmacology : RTP·2025
Same author

Considerations and derivations of permitted daily exposure limits for impurities from intravitreal pharmaceutical products.

Regulatory toxicology and pharmacology : RTP·2024
Same journal

The NTP Chronic Inhalation Study Does Not Support an Inherent Lung Cancer Hazard of Talc: Implications of Lung Particle Overload and Maximum Tolerated Dose.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Consideration of Carcinogenicity and Mode of Action Information by an Independent Expert Panel to Support Derivation of No-Significant-Risk-Level Values for Vinyl Acetate Monomer.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Which carcinogenicity study should I use? Automated identification of reliable studies.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Adoption of artificial intelligence in drug review across the lifecycle: Transformation of regulatory decision-making.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Cardiovascular outcomes following intrauterine and lactational exposure to cyantraniliprole in male Wistar rats.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Pesticide residue and mycotoxin occurrence in apples and their impact on human health in Morocco.

Regulatory toxicology and pharmacology : RTP·2026
See all related articles

Related Experiment Videos

Using default methodologies to derive an acceptable daily exposure (ADE).

Ellen C Faria1, Joel P Bercu2, David G Dolan3

  • 1Janssen Pharmaceutical Company, an Affiliate of Johnson & Johnson, United States.

Regulatory Toxicology and Pharmacology : RTP
|May 29, 2016
PubMed
Summary
This summary is machine-generated.

Deriving acceptable daily exposure (ADE) relies on various default approaches when complete health data is unavailable. Methods like the Threshold of Toxicological Concern (TTC) and Occupational Exposure Banding (OEB) offer protective strategies for early drug development.

Keywords:
Acceptable daily exposure (ADE)CleaningCross-contaminationDefaultMedian lethal dose (LD(50))Occupational exposure band (OEB)Permitted daily exposure (PDE)Therapeutic dose (TD)Threshold of toxicological concern (TTC)

Related Experiment Videos

Area of Science:

  • Pharmaceutical Science
  • Toxicology
  • Drug Development

Background:

  • Establishing health-based acceptable daily exposure (ADE) typically requires comprehensive nonclinical and clinical data.
  • In early drug development, limited or absent data necessitates alternative approaches for ADE derivation.
  • Default methods provide crucial decision-making support when chemical-specific health effect data is lacking.

Observation:

  • Various default ADE approaches exist, including toxicity estimates, fractions of therapeutic dose, cleaning limits, Threshold of Toxicological Concern (TTC), and Occupational Exposure Banding (OEB).
  • Each method has unique derivation, application, strengths, and limitations that must be considered.
  • These default strategies are employed when faced with toxicological and clinical data gaps.

Findings:

  • Default ADE methods must be as protective, or more so, than those derived from complete data packages to ensure patient safety.
  • Approaches like TTC and OEB, grounded in toxicological data, are preferred for early development ADEs.
  • Reliance on these toxicological data-based defaults supports decision-making while further data is collected.

Implications:

  • The use of validated default ADE approaches is critical for safeguarding patient health during early-stage drug development.
  • Hazard banding tools and TTC provide robust frameworks for managing risks associated with data-poor compounds.
  • Standardizing the application of protective default ADE strategies can enhance regulatory compliance and drug safety assessments.